small molecule

ONEXTON

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

Loss of exclusivityAugust 2029latest FDA-listed patent expiry
CompanyBAUSCH HEALTH AMERICAS INC

Drug detail

Brand nameONEXTON
Active ingredientBENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE
Strength3.75%;EQ 1.2% BASE
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalNovember 2014
Marketing statusRX

Listed patents

PatentExpiresType
8288434August 2029product
9561208June 2029product
10220049June 2029product
9504704June 2029product
10137142June 2029product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.